Thermo Fisher Scientific Inc.
TMO · New York Stock Exchange · USD
721,63USD
+26,87 (+3,87 %)Stand 9. Nov., 21:00
Vorbörslich722,00+0,37 (+0,05 %)5:41 ET
Kennzahlen
- Eröffnung
- 699,25
- Vortag
- 694,76
- Tagesspanne
- 692,39 – 723,03
- 52 Wochen
- 435,27 – 723,05
- Volumen
- 2,25 Mio.
- Ø Volumen
- 2,13 Mio.
- Börsenwert
- 267,38 Mrd. $
- KGV
- 38,0
- Gewinn je Aktie (TTM)
- 18,96
- Dividendenrendite
- 0,3 %
- Beta
- 0,8
- Nächste Zahlen
- 4. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 44,56 Mrd. | 42,88 Mrd. | 42,86 Mrd. | 44,92 Mrd. | 39,21 Mrd. |
| Herstellungskosten | 26,32 Mrd. | 25,15 Mrd. | 25,66 Mrd. | 25,9 Mrd. | 19,58 Mrd. |
| Bruttogewinn | 18,24 Mrd. | 17,73 Mrd. | 17,19 Mrd. | 19,01 Mrd. | 19,63 Mrd. |
| Forschung und Entwicklung | 1,4 Mrd. | 1,39 Mrd. | 1,34 Mrd. | 1,47 Mrd. | 1,41 Mrd. |
| Vertrieb und Verwaltung | 8,73 Mrd. | 8,68 Mrd. | 8,41 Mrd. | 9,02 Mrd. | 7,91 Mrd. |
| Operatives Ergebnis | 8,11 Mrd. | 7,66 Mrd. | 7,45 Mrd. | 8,53 Mrd. | 10,32 Mrd. |
| EBITDA | 11,47 Mrd. | 11,8 Mrd. | 11,2 Mrd. | 11,94 Mrd. | 11,97 Mrd. |
| Nettogewinn | 6,74 Mrd. | 6,34 Mrd. | 6 Mrd. | 6,95 Mrd. | 7,73 Mrd. |
| Gewinn je Aktie (verwässert) | 17,74 | 16,53 | 15,45 | 17,64 | 19,46 |
Umsatz nach Segment
Produkte · FY 2025
- Consumables18,66 Mrd. $41,89 %+6,12 %
- Service18,59 Mrd. $41,73 %+4,19 %
- Instruments7,3 Mrd. $16,39 %−1,95 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES23,03 Mrd. $51,69 %+2,35 %
- Europe11,83 Mrd. $26,54 %+8,93 %
- Asia Pacific8,1 Mrd. $18,18 %+1,82 %
- All Other Countries1,6 Mrd. $3,58 %+2,31 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 38,0
- Kurs-Umsatz-Verhältnis
- 5,6
- Kurs-Buchwert-Verhältnis
- 4,9
- PEG
- 4,0
- Bruttomarge
- 41,4 %
- Operative Marge
- 18,0 %
- Nettomarge
- 15,0 %
- Verschuldungsgrad
- 0,8
- EV/EBITDA
- 27,0
- Eigenkapitalrendite
- 13,3 %
- Kapitalrendite (ROIC)
- 7,5 %
- Free-Cashflow-Rendite
- 2,8 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 40,9 % | 41,3 % | 40,1 % | 42,3 % | 50,1 % |
| Operative Marge | 18,2 % | 17,9 % | 17,4 % | 19,0 % | 26,3 % |
| Nettomarge | 15,1 % | 14,8 % | 14,0 % | 15,5 % | 19,7 % |
| KGV | 32,6 | 31,4 | 34,2 | 31,1 | 34,0 |
| Kurs-Umsatz-Verhältnis | 4,9 | 4,6 | 4,8 | 4,8 | 6,7 |
| Kurs-Buchwert-Verhältnis | 4,1 | 4,0 | 4,4 | 4,9 | 6,4 |
| Verschuldungsgrad | 0,7 | 0,7 | 0,8 | 0,8 | 0,9 |
| Liquidität 3. Grades | 1,9 | 1,7 | 1,8 | 1,5 | 1,5 |
| Dividendenrendite | 0,3 % | 0,3 % | 0,3 % | 0,2 % | 0,2 % |
| Unternehmenswert | 247,41 Mrd. | 227,48 Mrd. | 233,23 Mrd. | 243,42 Mrd. | 294,75 Mrd. |
| EV/EBITDA | 21,6 | 19,3 | 20,8 | 20,4 | 24,6 |
| Eigenkapitalrendite | 12,6 % | 12,8 % | 12,8 % | 15,8 % | 18,9 % |
| Kapitalrendite (ROIC) | 7,6 % | 8,0 % | 8,0 % | 9,0 % | 10,7 % |
| Free-Cashflow-Rendite | 2,9 % | 3,7 % | 3,4 % | 3,2 % | 2,7 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +3,9 % | +0,1 % | −4,6 % | +14,5 % | +21,7 % |
| Bruttogewinn | +2,9 % | +3,1 % | −9,6 % | −3,2 % | +22,5 % |
| Operatives Ergebnis | +5,8 % | +2,9 % | −12,7 % | −17,4 % | +30,7 % |
| Nettogewinn | +6,3 % | +5,7 % | −13,7 % | −10,0 % | +21,2 % |
| Gewinn je Aktie | +7,3 % | +7,0 % | −12,4 % | −9,4 % | +21,8 % |
| Freier Cashflow | −13,4 % | +4,9 % | +0,2 % | −1,6 % | +3,0 % |
| Dividende je Aktie | +10,8 % | +12,6 % | +16,7 % | +15,8 % | +17,8 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 36Kaufen
- 7Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
694,27
Durchschnitt · −3,79 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 48 Mrd. | 50,57 Mrd. | 53,76 Mrd. |
| Umsatz (Tief – Hoch) | 47,8 Mrd. – 48,18 Mrd. | 50,33 Mrd. – 51,08 Mrd. | 52,97 Mrd. – 55,51 Mrd. |
| Gewinn je Aktie (Ø) | 25,29 | 27,74 | 30,63 |
| Gewinn je Aktie (Tief – Hoch) | 25,18 – 25,43 | 26,93 – 29,22 | 27,39 – 32,37 |
| Analysten | 15 | 16 | 6 |
Letzte Änderungen
- Argus Research30. Okt. 2026Buy
- Citigroup23. Okt. 2026Buy
- RBC Capital22. Okt. 2026Sector Perform
- Stifel22. Okt. 2026Buy
- TD Cowen22. Okt. 2026Buy
- Barclays22. Okt. 2026Overweight
- Baird22. Okt. 2026Outperform
- TD Cowen13. Okt. 2026Buy
Quartalszahlen
Nächste Zahlen: 4. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Jan. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Jan. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 6,40 | 5,72 | 5,25 | 6,45 | 5,50 | 5,23 | 5,10 | 5,94 |
| Gewinn je Aktie · Tatsächlich | 6,68 | 6,03 | 5,44 | 6,57 | 5,79 | 5,36 | 5,15 | 6,10 |
| Abweichung | +4,37 % | +5,42 % | +3,62 % | +1,86 % | +5,27 % | +2,49 % | +0,98 % | +2,69 % |
| Umsatz · Tatsächlich | 12,14 Mrd. | 11,99 Mrd. | 11,01 Mrd. | 12,22 Mrd. | 11,12 Mrd. | 10,86 Mrd. | 10,36 Mrd. | 11,4 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 15. Dez. 2026 | 15. Jan. 2027 | 0,47 |
| 15. Sept. 2026 | 15. Okt. 2026 | 0,47 |
| 15. Juni 2026 | 15. Juli 2026 | 0,47 |
| 13. März 2026 | 15. Apr. 2026 | 0,47 |
| 15. Dez. 2025 | 15. Jan. 2026 | 0,43 |
| 15. Sept. 2025 | 15. Okt. 2025 | 0,43 |
| 13. Juni 2025 | 15. Juli 2025 | 0,43 |
| 14. März 2025 | 15. Apr. 2025 | 0,43 |
| 13. Dez. 2024 | 15. Jan. 2025 | 0,39 |
| 13. Sept. 2024 | 15. Okt. 2024 | 0,39 |
| 14. Juni 2024 | 15. Juli 2024 | 0,39 |
| 14. März 2024 | 15. Apr. 2024 | 0,39 |
Aktiensplits
- 6. Juni 19963:2
- 25. Mai 19953:2
- 29. Okt. 19933:2
- 3. Nov. 19863:2
- 17. Sept. 19853:2
- 4. Jan. 19843:2
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 91,40 %
- Investoren mit 13F-Meldung
- 2.714
Größte Investoren
- BLACKROCK, INC.8,33 %30,92 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,54 %24,28 Mio.
- STATE STREET CORP4,52 %16,83 Mio.
- FMR LLC3,80 %14,08 Mio.
- MORGAN STANLEY2,90 %10,76 Mio.
- JPMORGAN CHASE & CO2,29 %8,5 Mio.
- GEODE CAPITAL MANAGEMENT, LLC2,26 %8,38 Mio.
- FRANKLIN TEMPLETON INC1,96 %7,27 Mio.
Insider-Geschäfte
- SPERLING SCOTT M28. Okt. 2026 · directorVerkauf3490 Aktien
- Britt Lisa P.28. Okt. 2026 · officer: Sr. VP and Chief HR OfficerVerkauf2831 Aktien · 706,45
- WEISLER DION J26. Sept. 2026 · directorKauf56 Aktien
- SPERLING SCOTT M26. Sept. 2026 · directorKauf63 Aktien
- Lynch Karen S26. Sept. 2026 · directorKauf46 Aktien
- Keith R. Alexandra26. Sept. 2026 · directorKauf46 Aktien
- JOHNSON JENNIFER M26. Sept. 2026 · directorKauf46 Aktien
- CASPER MARC N28. Aug. 2026 · director, officer: Chairman & CEOVerkauf725 Aktien · 622,18
Vergleichbare Unternehmen
Über das Unternehmen
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Führung
- Marc N. CasperChairman & CEO
- James MeyerSenior Vice President & Chief Financial Officer
- Gianluca PettitiPresident, COO & President of Products and Technologies
- Alan J. MalusSenior Vice President of Strategy & Corporate Development
- Thomas Bailey Shropshire Jr.Senior Vice President and General Counsel
- Lisa BrittChief Human Resources Officer & Senior Vice President
- CEO
- Marc N. Casper
- Mitarbeitende
- 125.000
- Hauptsitz
- Waltham, MA, US
- Sektor
- Healthcare
- Branche
- Medical - Diagnostics & Research
- Börsengang
- 17. März 1980
- Website
- thermofisher.com
Nachrichten
- Zacks Investment Research · 9. Nov., 9:20Should You Continue to Hold TMO Stock in Your Portfolio?
- Benzinga · 6. Nov., 10:21Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
- Seeking Alpha · 6. Nov., 9:35Diamond Hill Large Cap Fund Q3 2026 Portfolio Update
- Business Wire · 5. Nov., 17:15Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Business Wire · 5. Nov., 17:00Thermo Fisher Scientific Announces Quarterly Dividend
- Business Wire · 5. Nov., 8:30Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance
- 24/7 Wall Street · 4. Nov., 9:22Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over
- Defense World · 4. Nov., 5:0515,095 Thermo Fisher Scientific Inc. $TMO Shares Sold by Bank Julius Baer & Co. Ltd Zurich
- Defense World · 4. Nov., 4:25Thermo Fisher Scientific Inc. $TMO Shares Newly Bought by Associated Banc Corp
- Defense World · 3. Nov., 3:47Thermo Fisher Scientific Inc. $TMO Stock: BOCHK Asset Management Ltd Lowers Position
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.